BioSpace News Archive

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ:VRPX), today announced that preclinical studies of Probudur™, a proprietary patented injectable, long-acting “local anesthetic” Liposomal (Hydro) Gel Technology for postoperative pain management, have been initiated under an agreement with Charles River Laboratories

The Virtual Human Interaction Lab (VHIL) at Stanford University, the pioneering lab focused on the psychological and behavioral effects of virtual reality, announced today a new study in collaboration with MyndVR, the leading provider of VR solutions for older adults.

- Investigator-sponsored Phase 1 Trial of Acute GVHD Prophylaxis Following Allogeneic Hematopoietic Cell Transplantation Shows Encouraging Clinical Benefit and Promising Safety Profile when Combining Pacritinib 100 mg BID with Standard Immunosuppressive Therapy -

Prior to completion of the Arrangement, iCo, which is formed under the Business Corporations Act (British Columbia) is expected to continue under the CBCA and the Resulting Issuer will exist as a CBCA corporation.

New educational contest to begin in April in honor of HIV Long-Term Survivors Awareness Day and the 40th anniversary of the first publication defining HIV

We invite our shareholders and all interested parties to explore biotech small cap investment opportunities through two days of networking, dealmaking and discovery.

Eucure Biopharma, a subsidiary of Biocytogen focused on developing proprietary immuno-oncology antibodies, announced that its anti-CTLA-4 antibody (YH001), in combination with Junshi Biosciences’ anti-PD-1 monoclonal antibody,

ProMIS Neurosciences Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, is pleased to announce today the completion of an US$7M (CDN$8.75M) private placement of convertible unsecured debentures (the " Debentures ").

Managed Health Care Associates, Inc. (MHA), a leading health care services and software company focused on the alternate site health care provider marketplace, announces that Dr. Scott Gottlieb, 23rd Commissioner of the U.S. Food and Drug Administration (FDA), will deliver the keynote address at the MHA 2021 Business Summit.

By investing in an important and long-term way in the SSCB Stim Cell Bank and ReYou Suisse companies which are synergistic and complementary linked, Gaensel Energy Group Inc. thus confirms its intention to focus in the future, decisively on the stem cell and regenerative medicine sector.